Anti-FNDC3B monoclonal antibody

Pre-made anti-FNDC3B monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to FNDC3B/FNDC3B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0859-Ab-1/ GM-Tg-hg-IP0859-Ab-2Anti-Human FNDC3B monoclonal antibodyHuman
GM-Tg-rg-IP0859-Ab-1/ GM-Tg-rg-IP0859-Ab-2Anti-Rat FNDC3B monoclonal antibodyRat
GM-Tg-mg-IP0859-Ab-1/ GM-Tg-mg-IP0859-Ab-2Anti-Mouse FNDC3B monoclonal antibodyMouse
GM-Tg-cynog-IP0859-Ab-1/ GM-Tg-cynog-IP0859-Ab-2Anti-Cynomolgus/ Rhesus macaque FNDC3B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0859-Ab-1/ GM-Tg-felg-IP0859-Ab-2Anti-Feline FNDC3B monoclonal antibodyFeline
GM-Tg-cang-IP0859-Ab-1/ GM-Tg-cang-IP0859-Ab-2Anti-Canine FNDC3B monoclonal antibodyCanine
GM-Tg-bovg-IP0859-Ab-1/ GM-Tg-bovg-IP0859-Ab-2Anti-Bovine FNDC3B monoclonal antibodyBovine
GM-Tg-equg-IP0859-Ab-1/ GM-Tg-equg-IP0859-Ab-2Anti-Equine FNDC3B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0859-Ab-1/ GM-Tg-hg-IP0859-Ab-2; GM-Tg-rg-IP0859-Ab-1/ GM-Tg-rg-IP0859-Ab-2;
GM-Tg-mg-IP0859-Ab-1/ GM-Tg-mg-IP0859-Ab-2; GM-Tg-cynog-IP0859-Ab-1/ GM-Tg-cynog-IP0859-Ab-2;
GM-Tg-felg-IP0859-Ab-1/ GM-Tg-felg-IP0859-Ab-2; GM-Tg-cang-IP0859-Ab-1/ GM-Tg-cang-IP0859-Ab-2;
GM-Tg-bovg-IP0859-Ab-1/ GM-Tg-bovg-IP0859-Ab-2; GM-Tg-equg-IP0859-Ab-1/ GM-Tg-equg-IP0859-Ab-2
Products NameAnti-FNDC3B monoclonal antibody
Formatmab
Target NameFNDC3B
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-FNDC3B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0859-Ag-1Recombinant multi-species FND3B/ FNDC3B/ FAD104 protein


    Target information

    Target IDGM-IP0859
    Target NameFNDC3B
    Gene ID64778,72007,294925,694847,488169,101083793,615534,100057824
    Gene Symbol and Synonyms1600019O04Rik,FAD104,FNDC3B,mKIAA4164,PRO4979,RGD1311673,YV™2421
    Uniprot AccessionQ53EP0
    Uniprot Entry NameFND3B_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000075420
    Target ClassificationN/A

    The target: FNDC3B, gene name: FNDC3B, also named as FAD104, PRO4979, YV™2421. Enables RNA binding activity. Predicted to act upstream of or within several processes, including negative regulation of osteoblast differentiation; substrate adhesion-dependent cell spreading; and type II pneumocyte differentiation. Predicted to be located in endoplasmic reticulum. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.